Prenetics Global (NASDAQ:PRE) Trading Up 3.8%

Prenetics Global Limited (NASDAQ:PRE)’s stock price rose 3.8% during trading on Thursday . The stock traded as high as $5.36 and last traded at $4.97. Approximately 188,526 shares traded hands during mid-day trading, an increase of 77% from the average daily volume of 106,356 shares. The stock had previously closed at $4.79.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reduced their price target on shares of Prenetics Global from $10.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, April 4th.

Prenetics Global Price Performance

The business has a 50 day simple moving average of $4.40 and a 200-day simple moving average of $4.81. The stock has a market capitalization of $42.12 million, a price-to-earnings ratio of -0.96 and a beta of -0.11.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Monday, April 1st. The company reported ($0.52) earnings per share for the quarter. Prenetics Global had a negative net margin of 193.60% and a negative return on equity of 11.15%. The business had revenue of $5.43 million for the quarter. As a group, equities analysts predict that Prenetics Global Limited will post -3.59 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Prenetics Global stock. Nomura Holdings Inc. increased its position in shares of Prenetics Global Limited (NASDAQ:PRE) by 140.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 193,963 shares of the company’s stock after buying an additional 113,288 shares during the quarter. Nomura Holdings Inc. owned 2.12% of Prenetics Global worth $1,146,000 as of its most recent SEC filing. Institutional investors and hedge funds own 25.01% of the company’s stock.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.